Patents Examined by Robert A. Wax
  • Patent number: 11833205
    Abstract: The kaolinite composite diagnostic and therapeutic agent uses modified kaolinite as a carrier and is loaded with carbon nitride quantum dots and doxorubicin. The present disclosure provides a preparation method of the kaolinite composite diagnostic and therapeutic agent, including the following steps: S1: preparing the modified kaolinite by subjecting the pharmaceutical grade kaolinite to intercalation, exfoliation, and immersion wet etching; S2: subjecting the modified kaolinite and a carbon nitride quantum dot solution to ultrasonication, drying, and grinding to obtain a kaolinite composite containing the carbon nitride quantum dots; and S3: dissolving the doxorubicin in the dark, adding dissolved doxorubicin into the kaolinite composite containing the carbon nitride quantum dots, shaking in the dark for a period of time, and washing and drying to obtain the diagnostic and therapeutic agent containing the carbon nitride quantum dots and the doxorubicin.
    Type: Grant
    Filed: November 14, 2022
    Date of Patent: December 5, 2023
    Assignee: CHINA UNIVERSITY OF GEOSCIENCES (WUHAN)
    Inventors: Huaming Yang, Juan Liao
  • Patent number: 11833255
    Abstract: Provided is a nanoparticle comprising a pH-responsive polymer, a pH-insensitive polymer and a payload molecule. The nanoparticle can act as a system for delivery of the payload that releases the payload in a pH sensitive manner.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: December 5, 2023
    Assignees: The Brigham and Women's Hospital, Inc., Massachusetts Institute Of Technology
    Inventors: Sunandini Chopra, Rohit Karnik, Amy Wang, Omid C. Farokhzad, Xue-Qing Zhang
  • Patent number: 11833133
    Abstract: A solid oral pharmaceutical composition is disclosed, which comprises: a first active ingredient, which is pitavastatin or a pharmaceutically acceptable salt thereof; a second active ingredient, which is ezetimibe or a pharmaceutically acceptable salt thereof; and at least one excipient, including a diluent, a stabilizing agent, a disintegrant, a binding agent, a sweetener, a lubricant, a glidant, a flavor, a coloring agent or a combination thereof.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: December 5, 2023
    Assignee: ORIENT PHARMA CO., LTD.
    Inventors: Chien-Yu Chen, David Wong, Mongkol Sriwongjanya
  • Patent number: 11826488
    Abstract: Tissue product compositions and methods for treating a patient are provided. The tissue product composition may include a flowable carrier including a hyaluronic acid based material and acellular tissue matrix particles mixed within the carrier. Methods of producing the tissue product composition and an injection device filled with the tissue product composition are also provided.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: November 28, 2023
    Assignee: LifeCell Corporation
    Inventors: Hui Xu, Hui Li, Ming F. Pomerleau, Darin Messina
  • Patent number: 11826440
    Abstract: The present disclosure relates to, inter alia, a formulation comprising one or more active agents and one or more thermal stabilizing agents and is co-mingled with a first propellant that is a gas propellant prior to being filled under pressure into said package; the first propellant is added in sufficient amounts to be dispersed in the formulation; the package is under sufficient pressure suitable to expel the formulation as a whipped formulation upon application of external force on said formulation in said package. The present disclosure also relates to, inter alia, a method of preparing the disclosed formulation; a package comprising the disclosed formulation, and a method of using the disclosed formulation.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: November 28, 2023
    Assignees: FORMULATED SOLUTIONS, LLC, BEIERSDORF AG
    Inventors: Stephen Baldwin, Scott Carpenter, Nanhye Kim, Tom Meyer, Jerry Vancleave, Eric Dann, Thomas Dann, Renee Nelson, Brian Dann
  • Patent number: 11825845
    Abstract: The present invention provides materials and methods of making materials, where at least one surface of the material utilizes an emulsion to controllably release active agents, which can include hydrophilic agents, into the surrounding environment. Preferably, the materials are ‘slippery’ in that liquid droplets and other compounds, such as aqueous fluids, organic compounds and microorganisms, are able to easily slide off the surface without adhering to the surface. The active agents released by the emulsion may include antimicrobial agents, antifungal agents, antibacterial agents and other molecules that can kill or otherwise reduce the number of the pathogens. The resulting materials have improved anti-fouling behaviors compared to many other existing types of anti-fouling surfaces.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: November 28, 2023
    Inventors: David M. Lynn, Harshit Agarwal
  • Patent number: 11819570
    Abstract: A sugar-responsive gel that is highly resistant to temperature changes, and a sugar-responsive drug delivery device including such a gel. The sugar-responsive gel, which comprises a gel composition including a monomer having a hydroxyl group in addition to a phenylboronic-acid-based monomer, can exhibit suitable temperature resistance. A sugar-responsive drug delivery device including such a sugar-responsive gel is less susceptible to the effects of temperature changes, and therefore can prevent undesirable excessive delivery of a drug such as insulin.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: November 21, 2023
    Assignees: National University Corporation Tokai National Higher Education and Research System, National University Corporation Tokyo Medical and Dental University
    Inventors: Takayoshi Suganami, Miyako Tanaka, Akira Matsumoto, Hiroko Matsumoto, Yuki Morooka, Yuji Miyahara
  • Patent number: 11819578
    Abstract: The present disclosure generally relates to compositions and method for delivery, e.g., sustained delivery of active agents, and their use for the treatment of diseases or disorders.
    Type: Grant
    Filed: October 7, 2022
    Date of Patent: November 21, 2023
    Assignees: Trustees of Boston University, The General Hospital Corporation
    Inventors: Eric M. Bressler, Sarah Adams, Yolonda Colson, Mark W. Grinstaff, Wilson Wai Chun Wong
  • Patent number: 11819567
    Abstract: The disclosure provides chewable nicotine formulations comprising an orally-acceptable nicotine salt, an orally-acceptable alcohol, flavor components, and an orally-acceptable binder in a water-permeable, water-insoluble pouch, together with methods of making and using the same.
    Type: Grant
    Filed: December 19, 2022
    Date of Patent: November 21, 2023
    Inventor: Nirajkumar Karneshbhai Patel
  • Patent number: 11813289
    Abstract: The invention provides compositions and methods that comprise encapsulated silver diamine fluoride or other antimicrobial materials for use in treatment of dental caries, for example.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: November 14, 2023
    Assignee: ADVANTAGE SILVER DENTAL ARREST, LLC
    Inventors: Peter M. Milgrom, Jong Seto
  • Patent number: 11813269
    Abstract: The present invention provides for an oral liquid suspension that includes quetiapine or a pharmaceutically acceptable salt thereof. Also provided is a method for orally delivering quetiapine fumarate to a subject (e.g., for treating a mental disorder in a subject, such as schizophrenia, bipolar mania, and/or bipolar depression). The method includes orally administering to the subject an oral liquid suspension described herein.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: November 14, 2023
    Inventors: Paul Sudhakar, Scott Boyer
  • Patent number: 11801162
    Abstract: An apparatus for treating dry eye, comprising composition chambers respectively containing a first composition and a second composition, wherein the first composition includes 95%-100% of aqueous substances and the second composition includes 95-100% volume of non-aqueous substances; and an air pump that is fluidically connected to the composition chambers and sequentially generates and propels the mists of the first composition and the second composition to a surface that corresponds to a cornea of an eye. The first mist, including droplets of the one or more aqueous substances forms a first film layer that corresponds to an aqueous layer of an artificial tear film, the second mist has a volume within a range of 0.1-3 microliters, and includes droplets of the one or more non-aqueous substances forms a second film layer that corresponds to a lipid layer of the artificial tear film with a thickness within a range of 10 nm-200 nm.
    Type: Grant
    Filed: February 16, 2022
    Date of Patent: October 31, 2023
    Assignee: AURORA TEARS TECHNOLOGY, INC.
    Inventor: Ping Cerina Zhang
  • Patent number: 11801205
    Abstract: [Problem] Providing a whitened capsule and a whitened film without using any white pigment such as titanium dioxide. [Solution] Provided is a film, a capsule, and a film forming composition, characterized by comprising: a film-forming polymer; and a whitening agent including either a surfactant or both a surfactant and a salt, and characterized in that the surfactant is selected from a fatty acid ester of polyhydric alcohol, a polyethylene glycol, a polypropylene glycol, a polyalkylene oxide derivative, an alkyl sulfate ester salt, and a saponin.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: October 31, 2023
    Assignee: Capsugel Belgium NV
    Inventors: Kaori Sato, Takahisa Takubo, Hitomi Doi
  • Patent number: 11801214
    Abstract: A crosslinkable coating composition comprising: ingredient A that has at least two protons that can be activated to form a Michael carbanion donor; ingredient B that functions as a Michael acceptor having at least two ethylenically unsaturated functionalities each activated by an electron-withdrawing group; and a dormant carbamate initiator of Formula (1) wherein R1 and R2 can be independently selected from hydrogen, a linear or branched substituted or unsubstituted alkyl group having 1 to 22 carbon atoms; 1 to 8 carbon atoms; and An+ is a cationic species or polymer and n is an integer equal or greater than 1 with the proviso that An+ is not an acidic hydrogen; and optionally further comprising ammonium carbamate (H2NR1R2+?OC?ONR1R2). The crosslinkable coating composition can be used for a variety of coating applications including nail coating compositions.
    Type: Grant
    Filed: March 29, 2022
    Date of Patent: October 31, 2023
    Assignee: ELEMENTIS SPECIALTIES, INC.
    Inventors: Wouter Ijdo, Yanhui Chen, Prashant Deshmukh, Rajni Gupta, James A. Heck, Wayne Hoyte, Maurice Gray
  • Patent number: 11801225
    Abstract: This invention provides novel oral dosage forms comprising a hops extract. The oral dosage forms are capable of activating bitter taste receptors expressed in the gastrointestinal tract. The applications include but are not limited to the use of the oral dosage forms for reducing energy intake and/or appetite in a subject.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: October 31, 2023
    Assignee: THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED
    Inventors: John Ronald Ingram, Edward George Walker
  • Patent number: 11801262
    Abstract: Disclosed herein are antibiotic compositions, for example compositions that comprise a metal-containing agent and an organoselenium agent, and uses thereof.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: October 31, 2023
    Assignee: Thioredoxin Systems AB
    Inventors: Arne Holmgren, Jun Lu, Lili Zou
  • Patent number: 11793759
    Abstract: Lyophilized formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: October 24, 2023
    Assignee: ITERION THERAPEUTICS, INC.
    Inventors: Gowri Sukumar, Drazen Ostovic
  • Patent number: 11793878
    Abstract: The present invention relates to polyoxazoline polymers, polymer combinations and compositions comprising those polymers or combinations of polymers. The invention further relates to the use of said polyoxazoline polymers, said combinations and compositions comprising such polymers and combinations for the sustained release of one or more active ingredients, in particular one or more active pharmaceutical ingredients. It further relates to the use of polyoxazoline polymers or polymer combinations as drug carrier.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: October 24, 2023
    Assignee: Universiteit Gent
    Inventors: Maarten Vergaelen, Richard Hoogenboom, Victor Retamero de la Rosa, Chris Vervaet, Aseel Samaro, Valérie Vanhoorne
  • Patent number: 11793877
    Abstract: Embodiments of the invention relate generally to electrospun fibers and, more particularly, to the controlled release of an active pharmaceutical ingredient (API) from electrospun fiber scaffolds (EFSs).
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: October 24, 2023
    Assignee: Rensselaer Polytechnic Institute
    Inventors: Anthony R. D'Amato, Nicholas Schaub, Andrew Sante Fiumara, Paul Michael Troiano, Jesus Cardenas, Ryan J. Gilbert
  • Patent number: 11793754
    Abstract: A nanoemulsion, and a method of preparing the nanoemulsion is disclosed. The nanoemulsion includes sodium hypochlorite (NaOCl), chlorhexidine (CHX), and a self-nanoemulsifying delivery system (SNEDS) which further includes at least one oil, at least one surfactant, and at least one co-surfactant, wherein no parachloroaniline is present in the nanoemulsion after 1 hour at room temperature.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: October 24, 2023
    Assignee: King Abdulaziz University
    Inventor: Laila Ahmed Salim Bahammam